article thumbnail

Pharma responds to proposed EU pharmaceutical legislation reform

European Pharmaceutical Review

Pinsent Masons Charlotte Weekes, Senior Associate at Pinsent Masons shared with EPR : “The Commission’s ambitious pharma legislation review is the first significant review of the European system since 2004.” “It "Our concern is that the pharma legislation is not there yet."

article thumbnail

A glance back to Pharma Integrates, London 2022 – part ii

pharmaphorum

Run by Life Science Integrates, Pharma Integrates was in its 11th year in 2022. Nonetheless, she also mentioned that, over the summer, Lord Prior had written an article published in the British Medical Journal entitled ‘Precision public health must be at the centre of modern healthcare’. Highly unlikely.”

Pharma 76
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Sweeping changes in leaked EU pharma law draft reignite profit vs access conflict

Pharmaceutical Technology

The EU is planning a sweeping revision of its pharma legislation in March, the largest change in 20 years. The revision process is reviving old conflicts in the pharma industry over fair and affordable access to medicines versus Europe’s status as a competitive home for pharma innovation.

Pharma 64
article thumbnail

How can the pharma industry address the gap in talent recruitment and development?

pharmaphorum

Furthermore, by simulating real-life scenarios, AR offers the chance for staff in the pharma industry to practice complex operations without the associated risks. When it comes to recruitment, the pharmaceutical industry should be well placed to capitalise on a society that now has healthcare front of mind. Raising the profile.

article thumbnail

Specialty pharma’s next big opportunity: it’s time for patient access to adopt an open protocol

pharmaphorum

Along their journey, specialty pharma patients interact with a series of siloed institutions: clinics, specialty pharmacies, copay program vendors, patient assistance programs, nurses, etc. To diagnose the problem facing specialty pharma, a brief history lesson is in order. Visa’s attempted $5.3 Many are still making the transition.

article thumbnail

Interchangeability of biosimilars in the EU – the industry impact

European Pharmaceutical Review

Chris was named a ‘Rising Star’ in the 2022 Legal 500 Rankings for Life Sciences and Healthcare. Information guide for healthcare professionals, EMA and EU Commission updated 2/10/2019. In addition to his advisory and litigation work, Chris supports complex life sciences corporate transactions and private equity deals.

article thumbnail

Russia’s focus on domestic pharma production could shield it from sanctions’ effects

Pharmaceutical Technology

Although medicines tend to be excluded from trade sanctions as they cause loss of life, Russian pharma companies may struggle to secure funding in the face of economic sanctions and there may also be a disruption to non-essential medicines. Most pharma sites operating in Russia are owned by domestic companies.

Pharma 122